×
Home
Archive Submission Guidelines
News Contact
Review article
Crossmark

Angiogenesis in glioblastoma: Molecular and cellular mechanisms and clinical applications

By
Desanka Tasić ,
Desanka Tasić
Irena Dimov ,
Irena Dimov
Miloš Kostov ,
Miloš Kostov
Nataša Vidović ,
Nataša Vidović
Dragan Dimov
Dragan Dimov

Abstract

Glioblastoma (GBM) is the most common malignant primary brain tumor in adults and carries poor prognosis. Despite advances in therapy, no significant increase in survival has been achieved for GBM patients. These tumors inevitably recur in the majority of patients, and the therapeutic options for recurrent tumors are limited. GBMs are aggressive, fast-growing, and highly infiltrative tumors, with exuberant angiogenesis (microvascular proliferation) and necrosis. However, the newly formed tumor vessels are structurally and functionally abnormal, creating areas of hypoxia and ultimately necrosis, contributing to tumor progression and aggressiveness. Since GBMs are hypervascular in nature, targeting tumor angiogenesis emerged as a promising therapeutic strategy. In this review, we summarized the molecular and cellular mechanisms governing GBM angiogenesis, the other modes of tumor vascularization, and the key mediators of these processes. We also discussed the importance of tumor hypoxia in promoting angiogenic and vasculogenic processes, the contributions of GBM stem cells to tumor vasculature, the anti-angiogenic therapy for GBM, and the resistance to such therapy. A better understanding of the molecular and cellular basis of GBM neovascularization, the mechanisms of resistance to therapy, and the contributions of GBM stem cells to tumor vasculature will lead to the development of more effective treatment strategies.

References

1.
Shaked Y, Ciarrocchi A, Franco M, Lee CR, Man S, Cheung AM, et al. Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors. Science. 2006;313(5794):1785–7.
2.
Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine & Growth Factor Reviews. 2010;21(1):21–6.
3.
Umemura N, Saio M, Suwa T, Kitoh Y, Bai J, Nonaka K, et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. Journal of Leukocyte Biology. 2008;83(5):1136–44.
4.
Raychaudhuri B, Rayman P, Huang P, Grabowski M, Hambardzumyan D, Finke JH, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. Journal of Neuro-Oncology. 2015;122(2):293–301.
5.
Saio. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. International Journal of Oncology. 2009;34(6).

Citation

Article metrics

Google scholar: See link

Citations

Crossref Logo

2

Crossref Logo

S. Daisy Precilla, Indrani Biswas, Shreyas S. Kuduvalli, T.S. Anitha

(2022)

Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?

Cellular Signalling, 95()

10.1016/j.cellsig.2022.110350

Crossref Logo

Candice C. Poon, Shelley M. Herbrich, Yulong Chen, Anwar Hossain, Gregory N. Fuller, Sonali Jindal, Sreyashi Basu, Daniel Ledbetter, Marc Macaluso, Lynnette M. Phillips, Joy Gumin, Zhong He, Brittany C. Parker Kerrigan, Sanjay K. Singh, Pratishtha Singh, Mohammed Fayyad Zaman, Derek Ng Tang, Sangeeta Goswami, Frederick F. Lang, Padmanee Sharma

(2025)

Mesenchymal Stem Cells and Fibroblasts Contribute to Microvascular Proliferation in Glioblastoma and are Correlated with Immunosuppression and Poor Outcome

Cancer Immunology Research, 13(6)

10.1158/2326-6066.CIR-24-0743

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.